Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092298 | 0.99 | CHRM2 (0.35) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL25247792 | 0.85 | TLR8 (0.42) | USP2SMN1; SMN2TLR8TSHRACKR3 | |
| SCHEMBL932920 | 0.82 | TEAD3 (0.38) | SMN1; SMN2TDP1TSHR | |
| SCHEMBL31217976 | 0.81 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL31217905 | 0.81 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL12092286 | 0.81 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL12092164 | 0.80 | EPHX2 (0.42) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL25242965 | 0.80 | USP2 (0.43) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL23251655 | 0.78 | USP2 (0.46) | CHRM2CHRM4CHRM1CHRM3USP2 | |
| SCHEMBL10072933 | 0.78 | USP2 (0.49) | CHRM2CHRM4CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | CHRM2 4282/4885CHRM4 4214/4885CHRM1 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.